Dupixent scores a first in rare skin disease prurigo nodularisSanofi and Regeneron’s Dupixent has become the first biologic drug to show activity in prurigo nodularis (PN), raising Share XDupixent scores a first in rare skin disease prurigo nodularishttps://pharmaphorum.com/news/dupixent-scores-a-first-in-rare-skin-disease-prurigo-nodularis/
